On May 21, 2026, Eli Lilly delivered very positive news about its Phase 3 TRIUMPH-1 obesity trial
This is troubling, since those who discontinue early miss out on the long-term weight loss and health improvements that typically accrue after 3+ months of therapy
NYSE: PFE Key Data Points Similar results and a less frequent medication regimen could help Pfizer become a main player in the GLP-1 space, even though it is late to the party
For example, semaglutide can help you lose 15% of your weight in 68 weeks, while an older drug, Contrave, has been shown to result in closer to a 5% weight loss
For this reason, I counsel my patients to proceed with caution." All of this is not to say that nutrition can't play a role in boosting GLP-1 production